FREE Account Opening + No Clearing Fees
Loading...
Genpharmasec Rights Issue 2024 Detail
Issue Open January 23, 2024
Issue Close February 13, 2024
Issue Size (Shares) 27.69 Crores
Issue Size (Amount) ₹48.45 Crores
Issue Price ₹2 per Share
Listing At BSE

Genpharmasec Rights Issue 2024 Date & Price FAQs

Genpharmasec Rights Issue 2024 Timetable

Last Date for credit of Rights Entitlements
Last Date for renunciation of Rights EntitlementsFebruary 2, 2024
Issue Opening DateJanuary 23, 2024
Issue Closing DateFebruary 13, 2024
Allotment DateFebruary 16, 2024
Shares Credit DateFebruary 21, 2024
Listing DateFebruary 26, 2024

Genpharmasec Rights Issue 2024 price is set at ₹2 per Share. The Genpharmasec Rights Issue 2024 opens on January 23, 2024, and closes on February 13, 2024, for the subscription.

The allotment of Genpharmasec Rights Issue 2024 is expected to happen on or about February 16, 2024 as per the issue schedule.

Genpharmasec Rights Issue 2024 expected to list on or around February 26, 2024.

The credit of Genpharmasec Rights Issue 2024 in Demat account is expected on or about February 21, 2024 as per the issue schedule.

The company proposes to utilize the net proceeds from the Issue towards funding the following objects:

  1. To acquire Equity Shares from existing shareholders of Derren Healthcare Private Limited and make it a subsidiary Company
  2. To repay or prepay, in full or in part, certain Borrowings availed by our Company.
  3. To part finance the requirement of Working Capital;
  4. To meet General corporate purposes;
  5. To meet the expenses of the Issue.

It is difficult to say at what price Genpharmasec Rights Issue 2024 shares will list. The price depends on the demand and supply of company's shares on the day of listing.

Sorry, we do not provide rights issue's recommendations. But we share a lot of information about Genpharmasec Rights Issue 2024 which could help you with questions like Genpharmasec Rights Issue 2024 buy or not? Consider reading Genpharmasec Rights Issue 2024 reviews and analysis from experts posted on rights issue detail page.